The role of cGMP hydrolysing phosphodiesterases 1 and 5 in cerebral artery dilatation

European Journal of Pharmacology

Volumn 420, Issue 1, 2001, Pages 55-65

  Kruuse, Christina ^a   Rybalkin, Sergei D ^b   Khurana, Tejvir S ^a   Jansen Olesen, Inger ^c   Olesen, Jes ^a   Edvinsson, Lars ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Cerebral artery; cGMP; Nitric oxide (NO); Phosphodiesterase; Phosphodiesterase inhibitor; Vasodilatation

Indexed keywords

1H 1,2,4 OXADIAZOLO[4,3 A]QUINOXALIN 1 ONE; 3 ISOBUTYL 8 METHOXYMETHYL 1 METHYLXANTHINE; ATRIAL NATRIURETIC FACTOR; CYCLIC AMP; CYCLIC GMP; DIPYRIDAMOLE; GUANYLATE CYCLASE; ISOBUTYLMETHYLXANTHINE; MILRINONE; NITRIC OXIDE; NITROPRUSSIDE SODIUM; PENTOXIFYLLINE; PHOSPHODIESTERASE; PHOSPHODIESTERASE 1A; PHOSPHODIESTERASE 1B; PHOSPHODIESTERASE 1C; PHOSPHODIESTERASE I; PHOSPHODIESTERASE V; UNCLASSIFIED DRUG; ZAPRINAST;

ANIMAL TISSUE; ARTERY DILATATION; ARTICLE; BASILAR ARTERY; CONTROLLED STUDY; DRUG POTENTIATION; ENZYME ACTIVITY; ENZYME ASSAY; GUINEA PIG; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYDROLYSIS; IMMUNOREACTIVITY; MALE; NONHUMAN; PRIORITY JOURNAL; VASOMOTOR REFLEX;

1-METHYL-3-ISOBUTYLXANTHINE; 3',5'-CYCLIC-GMP PHOSPHODIESTERASE; ANIMALS; BASILAR ARTERY; CEREBRAL ARTERIES; CYCLIC AMP; CYCLIC GMP; DIPYRIDAMOLE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; ENZYME INHIBITORS; GUANYLATE CYCLASE; GUINEA PIGS; ISOENZYMES; MALE; MILRINONE; NITROPRUSSIDE; OXADIAZOLES; PENTOXIFYLLINE; PHOSPHODIESTERASE INHIBITORS; PURINONES; QUINOXALINES; VASODILATION; VASODILATOR AGENTS;

EID: 0035907996     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(01)01010-X     Document Type: Article

References (43)

1. Phosphodiesterase inhibitors: Their comparative effectiveness in vitro in various organs
2. Effects of selective inhibitors on cyclic nucleotide phosphodiesterases of rabbit aorta
3. Cyclic nucleotide phosphodiesterases: Functional implications of multiple isoforms
4. Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitors
5. Characterization of cyclic nucleotide phosphodiesterases with cyclic GMP analogs: Topology of the catalytic domains
6. Nitric oxide directly activates calcium-dependent potassium channels in vascular smooth muscle
7. Sildenafil: An orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction
8. HN-10200 causes endothelium-independent relaxations in isolated canine arteries
9. Nitric oxide and the cerebral circulation
10. Role of soluble guanylate cyclase in dilator responses of the cerebral microcirculation
11. Molecular cloning and characterization of a distinct human phosphodiesterase gene family: PDE11A
12. Isolation and characterization of PDE9A, a novel human cGMP-specific phosphodiesterase
13. Cloning and characterization of a novel human phosphodiesterase that hydrolyzes both cAMP and cGMP (PDE10A)
14. Potent and selective inhibition of nitric oxide-sensitive guanylyl cyclase by 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one
15. Human alpha-calcitonin gene-related peptide stimulates adenylate cyclase and guanylate cyclase and relaxes rat thoracic aorta by releasing nitric oxide
16. Differential vasorelaxant effects of milrinone and amrinone on contractile responses of canine coronary, cerebral, and renal arteries
17. Phosphodiesterase isozyme inhibition and the potentiation by zaprinast of endothelium-derived relaxing factor and guanylate cyclase stimulating agents in vascular smooth muscle
18. Nitric oxide synthase inhibition and cerebrovascular regulation
19. Similar responsiveness of smooth muscle of the canine basilar artery to EDRF and nitric oxide
20. Reduced production of cGMP underlies the loss of endothelium-dependent relaxations in the canine basilar artery after subarachnoid hemorrhage
21. Effects of the non-selective phosphodiesterase inhibitor pentoxifylline on regional cerebral blood flow and large arteries in healthy subjects
22. Dipyridamole dilates large cerebral arteries concomitant to headache induction in healthy subjects
23. An in vitro study of the pharmacological responses of rat middle cerebral artery: Effects of overnight storage
24. Effects of selective phosphodiesterase inhibitors on isolated coronary, lung and renal arteries from man and rat
25. Modulation of vascular cyclic nucleotide phosphodiesterases by cyclic GMP: Role in vasodilatation
26. Phosphodiesterase inhibitors induce endothelium-dependent relaxation of rat and rabbit aorta by potentiating the effects of spontaneously released endothelium-derived relaxing factor
27. Contractile properties of small arterial resistance vessels in spontaneously hypertensive and normotensive rats
28. Inhibitors of cyclic nucleotide phosphodiesterases as therapeutic agents
29. Cyclic nucleotides and cerebrovascular tone in newborn pigs
30. Cyclic nucleotide crosstalk and the regulation of cerebral vasodilation
31. Interaction of endothelium with dilation produced by inhibitors of cyclic nucleotide diesterases in mouse brain arterioles in vivo
32. Calmodulin-stimulated cyclic nucleotide phosphodiesterase (PDE1C) is induced in human arterial smooth muscle cells of the synthetic, proliferative phenotype
33. Nitric oxide/cAMP interactions in the control of rat renal vascular resistance
34. Effect of endothelium on basal and on stimulated accumulation and efflux of cyclic GMP in rat isolated aorta
35. The nitric oxide and cGMP signal transduction system: Regulation and mechanism of action
36. Impaired cerebral vasodilator responses to NO and PDE V inhibition after subarachnoid hemorrhage
37. Cloning and characterization of a cAMP-specific cyclic nucleotide phosphodiesterase
38. Role of selective cyclic GMP phosphodiesterase inhibition in the myorelaxant actions of M&B 22,948, MY-5445, vinpocetine and 1-methyl-3-isobutyl-8-(methylamino)xanthine
39. Cyclic nucleotide phosphodiesterases as therapeutic targets in cardiovascular diseases
40. Identification, characterization and functional role of phosphodiesterase isozymes in human airway smooth muscle
41. Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro
42. Cyclic GMP-phosphodiesterase inhibition does not alter cerebral oxygen consumption
43. Identification, characterization, and functional role of phosphodiesterase type IV in cerebral vessels: Effects of selective phosphodiesterase inhibitors